Have a question about this calculator? Get a detailed answer.
The Caprini Risk Assessment Model (RAM) is a validated, point-based scoring system used to stratify individual patient risk for venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE). Originally developed by Joseph Caprini in 2005 and subsequently revised with additional risk factors, it assigns weighted points (1, 2, 3, or 5) to over 40 clinical risk factors across categories including age, surgery type, mobility status, medical conditions, thrombophilic conditions, and prior thromboembolic history. Age 41–60 scores 1 point; minor surgery 1 point; obesity (BMI >25) 1 point; active cancer 3 points; prior VTE 3 points; known thrombophilia 3 points; stroke or spinal cord injury within 30 days 5 points; and elective lower extremity arthroplasty 5 points. Total score determines risk category: low risk (0–1 point), moderate risk (2 points), high risk (3–4 points), and very high risk (5 or more points). These categories guide prophylaxis recommendations: low risk — early ambulation only; moderate risk — pharmacological prophylaxis (LMWH or unfractionated heparin) or compression devices; high risk — pharmacological plus mechanical prophylaxis; very high risk — extended pharmacological prophylaxis (up to 28–35 days post-operatively). The Caprini RAM was developed primarily for surgical patients but has been applied broadly across medical and cancer populations. It has been validated in numerous prospective studies demonstrating that very high-risk patients (Caprini ≥5) have VTE rates of over 6% without prophylaxis. It is endorsed by the American College of Chest Physicians (ACCP) and used widely in perioperative care.
Caprini Score = sum of weighted risk factor points; 0–1 = low risk; 2 = moderate risk; 3–4 = high risk; ≥5 = very high risk; ≥2 = consider pharmacological prophylaxis
- 1Step 1 — Identify 1-point factors: Age 41–60, minor surgery, BMI >25, varicose veins, swollen legs, oedema, prior major surgery in 30 days, medical patient at bed rest, sepsis <30 days, inflammatory bowel disease, morbid obesity.
- 2Step 2 — Identify 2-point factors: Age 61–74, arthroscopic surgery, malignancy, major open surgery >45 min, laparoscopic surgery >45 min, central venous access, confined to bed >72h, immobilising cast, medical patient ICU.
- 3Step 3 — Identify 3-point factors: Age ≥75, prior VTE history, family history VTE, factor V Leiden, prothrombin 20210A, antiphospholipid antibodies, elevated homocysteine, heparin-induced thrombocytopenia, protein C/S deficiency.
- 4Step 4 — Identify 5-point factors: Stroke or paralysis, SCI, hip/pelvis/leg fracture <30 days, elective hip/knee arthroplasty, acute MI <30 days, CHF within 30 days, COPD exacerbation.
- 5Step 5 — Calculate total score by summing all applicable risk factor points.
- 6Step 6 — Assign risk category and prophylaxis recommendation: Low (0–1) = ambulation; Moderate (2) = pharmacological or mechanical; High (3–4) = combined; Very High (≥5) = extended prophylaxis.
- 7Step 7 — Balance against bleeding risk: Always weigh VTE prophylaxis benefit against patient-specific bleeding risk before prescribing pharmacological agents. Use local bleeding risk criteria.
Very high risk — extended LMWH prophylaxis for 28–35 days post-op; add compression stockings
Age 61–74 = 2 points + BMI >25 = 1 + elective arthroplasty = 5. Total = 8 = very high risk. ACCP guidelines recommend extended VTE prophylaxis post-arthroplasty.
Multiple 1-point factors accumulate to very high risk; pharmacological plus mechanical prophylaxis
Age 41–60=1, minor surgery=1, varicose veins=1, BMI>25=1, bed rest>72h=1. Total=5=very high risk despite each individual factor appearing mild.
Extreme VTE risk — anticoagulation plan must balance against surgical bleeding risk; haematology input
Active cancer=3, prior VTE=3, thrombophilia=3, major surgery=2, age 41–60=1. Total=12. Maximum extended LMWH post-op; consider bridging anticoagulation discussion.
Low risk — early ambulation; mechanical prophylaxis optional; no routine pharmacological prophylaxis
Age <40=0, minor surgery=1. Total=1=low risk. Routine pharmacological VTE prophylaxis not indicated. Early mobilisation encouraged.
Pre-operative surgical risk assessment to determine need for VTE prophylaxis type and duration. This application is commonly used by professionals who need precise quantitative analysis to support decision-making, budgeting, and strategic planning in their respective fields
Post-operative extended prophylaxis decisions in high-risk cancer and orthopaedic surgery patients. Industry practitioners rely on this calculation to benchmark performance, compare alternatives, and ensure compliance with established standards and regulatory requirements
Hospital VTE prevention programme implementation and quality improvement audit. Academic researchers and students use this computation to validate theoretical models, complete coursework assignments, and develop deeper understanding of the underlying mathematical principles
Anaesthetic pre-assessment clinics for DVT risk stratification before elective procedures. Financial analysts and planners incorporate this calculation into their workflow to produce accurate forecasts, evaluate risk scenarios, and present data-driven recommendations to stakeholders
Medical-legal and national audit documentation of VTE prophylaxis decision-making. This application is commonly used by professionals who need precise quantitative analysis to support decision-making, budgeting, and strategic planning in their respective fields
Heparin-Induced Thrombocytopenia (HIT)
{'title': 'Heparin-Induced Thrombocytopenia (HIT)', 'body': 'HIT is a paradoxical prothrombotic complication of heparin therapy in which antibodies against heparin-PF4 complexes cause platelet activation and thrombosis. HIT history scores 3 points on Caprini. In HIT patients, all heparin products (including LMWH) are absolutely contraindicated. Alternative anticoagulants (argatroban, fondaparinux, danaparoid) must be used for VTE prophylaxis.'}
Antiphospholipid Syndrome (APS)
{'title': 'Antiphospholipid Syndrome (APS)', 'body': 'APS (antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, beta-2 glycoprotein I antibodies) scores 3 points on Caprini. This autoimmune thrombophilia carries very high VTE and arterial thrombosis risk. Patients with APS and prior thrombosis typically require long-term anticoagulation (warfarin INR 2–3), not just perioperative prophylaxis.'} This edge case frequently arises in professional applications of caprini score where boundary conditions or extreme values are involved. Practitioners should document when this situation occurs and consider whether alternative calculation methods or adjustment factors are more appropriate for their specific use case.
Cancer Surgery Patients
{'title': 'Cancer Surgery Patients', 'body': 'Cancer patients undergoing major surgical resection have extremely high VTE risk. ASCO and ACCP guidelines recommend extended pharmacological prophylaxis (28 days) after major abdominal and pelvic cancer surgery. Active cancer scores 2 points on Caprini (some adaptations give 3 points), often placing cancer surgery patients directly into very high-risk categories.'}
Renal Impairment and LMWH Dosing
{'title': 'Renal Impairment and LMWH Dosing', 'body': 'LMWH is renally cleared and accumulates in severe renal impairment (eGFR <30 mL/min), increasing bleeding risk. Dose reduction or monitoring of anti-Xa levels is required. Unfractionated heparin (UFH, 5,000 units TDS SC) is preferred in severe renal failure as it is not renally cleared. Fondaparinux is contraindicated if eGFR <20.'}
| Points | Example Risk Factors |
|---|---|
| 1 point each | Age 41–60, minor surgery, BMI >25, varicose veins, swollen legs, IBD, bed rest, sepsis <30d |
| 2 points each | Age 61–74, major open surgery >45 min, malignancy, central venous line, bed rest >72h, cast |
| 3 points each | Age ≥75, prior VTE, family history VTE, thrombophilia (Factor V, prothrombin, APS), HIT |
| 5 points each | Stroke/paralysis, SCI, hip/pelvis/leg fracture, elective arthroplasty, acute MI, CHF, COPD |
| Risk Category | Caprini Score → Recommendation |
| Low | 0–1 → Early ambulation only |
| Moderate | 2 → Pharmacological or mechanical prophylaxis |
| High | 3–4 → Pharmacological + mechanical prophylaxis |
| Very High | ≥5 → Extended pharmacological prophylaxis |
What is the difference between Caprini and Padua scores?
Both are VTE risk stratification tools but for different settings. The Caprini RAM was validated primarily in surgical patients and contains 40+ risk factors across multiple categories. The Padua Prediction Score was designed for medical inpatients and uses 11 simpler risk factors, making it quicker to apply on general wards. The Caprini is more comprehensive and better validated in complex surgical populations.
What is extended VTE prophylaxis and when is it used?
Standard in-hospital VTE prophylaxis ends at hospital discharge. Extended prophylaxis continues LMWH or apixaban for 28–35 days post-operatively in very high-risk patients, particularly after hip and knee arthroplasty, major cancer surgery, and hip fracture surgery. Studies show VTE rates remain elevated for 4–6 weeks post-operatively in high-risk populations. In practice, this concept is central to caprini score because it determines the core relationship between the input variables.
How should pharmacological prophylaxis be chosen in high-risk patients?
LMWH (low molecular weight heparin, e.g., enoxaparin 40 mg OD or dalteparin 5,000 units OD) is the standard first-line pharmacological prophylaxis. Unfractionated heparin (UFH) is preferred in severe renal impairment. Direct oral anticoagulants (DOACs — rivaroxaban, apixaban) are approved alternatives for specific surgical settings including arthroplasty. The process involves applying the underlying formula systematically to the given inputs. Each variable in the calculation contributes to the final result, and understanding their individual roles helps ensure accurate application.
When is mechanical prophylaxis preferred over pharmacological?
Mechanical prophylaxis (graduated compression stockings or intermittent pneumatic compression devices) is preferred when pharmacological agents are contraindicated: active bleeding, recent intracranial surgery, severe thrombocytopenia, or high bleeding risk surgery. Mechanical and pharmacological prophylaxis are combined in very high-risk patients. This applies across multiple contexts where caprini score values need to be determined with precision. Common scenarios include professional analysis, academic study, and personal planning where quantitative accuracy is essential.
Is the Caprini score validated in cancer patients?
The Khorana Score is specifically developed and validated for ambulatory cancer patients receiving chemotherapy. The Caprini RAM is more commonly used in surgical oncology patients perioperatively. Some cancer centres use Caprini for pre-operative risk stratification with specific additional cancer-related risk factors. Both tools have limited precision in complex oncology populations.
How does pregnancy affect VTE risk and Caprini scoring?
Pregnancy increases VTE risk approximately 4–5 fold due to hypercoagulability, venous stasis, and vessel wall changes. The RCOG Green-top Guideline uses a separate risk assessment model for pregnancy. Standard Caprini scoring does not adequately capture obstetric-specific risk factors. All pregnant patients should be assessed using obstetric-specific VTE risk tools. The process involves applying the underlying formula systematically to the given inputs.
What is the VTE rate by Caprini risk category without prophylaxis?
Without prophylaxis, approximate VTE rates are: low risk (0–1) <0.5%; moderate risk (2) ~0.5–1%; high risk (3–4) ~1–3%; very high risk (≥5) ~6% or higher. These rates are based on objectively confirmed DVT, primarily from surgical trials. Rates in specific high-risk populations (major cancer surgery, arthroplasty) can exceed 10–20% without prophylaxis.
What is the Caprini score threshold for pharmacological VTE prophylaxis?
The ACCP guideline threshold for recommending pharmacological VTE prophylaxis is generally Caprini score ≥2 (moderate risk) in surgical patients. At this level, the benefit of LMWH prophylaxis outweighs bleeding risk in most surgical populations. Individual patient bleeding risk factors must always be assessed before prescribing any anticoagulant. In practice, this concept is central to caprini score because it determines the core relationship between the input variables.
Pro Tip
Build a Caprini score systematically using the checklist approach — review all 1-point factors first (most patients have several), then 2-point, 3-point, and 5-point factors. A patient with five 1-point factors (age 50, BMI 27, bed rest, varicose veins, minor surgery) scores 5 and meets very high-risk criteria despite no single alarming factor. Always document the score in the clinical notes.
Did you know?
Joseph Caprini published the original Risk Assessment Model in 2005 based on data from over 8,000 surgical patients. By 2015, his model had been cited over 1,000 times in peer-reviewed literature. Caprini also holds patents for textile-based prophylaxis devices and has been a pioneer in integrating systematic VTE risk assessment into routine surgical care — a practice that has prevented hundreds of thousands of VTE deaths annually.
References
- ›Caprini JA — Thrombosis Risk Assessment as a Guide to Quality Patient Care (Dis Mon 2005)
- ›ACCP Antithrombotic Therapy and Prevention of Thrombosis Guidelines 9th Ed
- ›Shuman AG et al. — Caprini Validation in Head and Neck Surgery (Laryngoscope 2012)
- ›NHS England — VTE Prevention Guidance
- ›LITFL Caprini Score VTE Risk Assessment
Read the full guide on how to use this calculator effectively
Read more →Get Weekly Math Tips
Join 12,000+ subscribers who get calculator tips every week.